Lakefront Biotherapeutics (GLPGF) Long-Term Investments (2020 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Long-Term Investments for 5 consecutive years, with $56.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 4.9% year-over-year to $56.1 million in Q1 2026; TTM through Mar 2026 was $56.1 million, a 4.9% increase from a year earlier, with the FY2025 full-year figure at $52.9 million, down 7.7% from the prior year.
• Long-Term Investments was $56.1 million for Q1 2026 at Lakefront Biotherapeutics, up from $54.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $56.6 million in Q4 2024 and troughed at $14.6 million in Q4 2023.
• A 4-year average of $49.6 million and a median of $54.2 million in 2025 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments jumped 287.33% in 2024 and retreated 3.69% in 2025, its largest moves.
• Over 4 years, Long-Term Investments stood at $14.6 million in 2023, then jumped by 287.33% to $56.6 million in 2024, then declined by 3.69% to $54.5 million in 2025, then rose by 2.99% to $56.1 million in 2026.
• The last three Long-Term Investments figures came in at $56.1 million (Q1 2026), $54.5 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.